The French island of Mayotte faces one of the highest cervical cancer death rates in Europe, with public health officials warning that routine screening remains critically low and unevenly accessed. According to the Regional Cancer Coordination Committee (CRCDC) of Mayotte, fewer than 30% of eligible women undergo screening annually, leaving thousands at risk of late-stage diagnoses when treatment is far less effective.
Why screening rates lag in Mayotte
Barriers to cervical cancer screening include geographic isolation, cultural stigma around women’s health, and a lack of mobile outreach programs. “We have to go out and find these women,” said the CRCDC, emphasizing that passive screening models—relying on women to seek care—are failing in a region where transportation and awareness are major hurdles. The island’s health system, already strained by limited resources, has expanded free screening initiatives in recent months, but uptake remains uneven across its five districts.
Mayotte’s cervical cancer mortality rate is nearly double the national average in France, with Indigenous communities disproportionately affected. A 2023 report from Mayotte’s health authorities highlighted that 60% of cervical cancer cases are diagnosed at advanced stages, when survival rates drop below 50%. “Early detection saves lives, but we’re still missing too many women entirely,” said a spokesperson for the island’s regional health agency.
How local governments are responding
In June, the municipalities of Vitry-sur-Seine and Bonneuil-sur-Marne—both with significant Mayotte-born populations—announced free cervical cancer screening drives, targeting women who may not have access to regular healthcare. Meanwhile, Mayotte’s prefecture has partnered with local clinics to offer mobile screening units, though logistical challenges persist. “We’re not just waiting for women to come to us,” said a public health official. “We’re taking the tools to them, but we need more funding to scale this up.”
Health advocates note that while screening programs have improved, cultural and systemic barriers remain. A 2022 study published in the Bulletin Épidémiologique Hebdomadaire found that women in Mayotte were twice as likely to delay screening due to misinformation about HPV vaccines or fear of invasive procedures. “Education is just as critical as access,” said Natacha Helme, a gynecologist with Outre-Mer La 1ère, who has worked on cervical cancer prevention in the region. “Many women don’t realize how simple and effective screening can be.”
What’s next for cervical cancer prevention in Mayotte
Planned expansions include a pilot program in 2025 to integrate HPV vaccination into school-based health initiatives, though rollout will depend on vaccine supply and community acceptance. The CRCDC has also called for a dedicated cervical cancer registry to track screening trends and outcomes, a step that could inform future policy. For now, officials urge women in Mayotte to prioritize screening, emphasizing that the procedure—whether a Pap test or HPV test—takes less than 10 minutes and can prevent 70% of cervical cancer cases.
For those without local access, the French national health system offers free screening for all women aged 25–65, with priority given to underserved regions. Information on mobile units and appointment scheduling is available through Mayotte’s health department.
